Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-031/4985
A61K-009/00
A61K-031/48
A61K-031/10
출원번호
US-0471334
(2017-03-28)
등록번호
US-10172853
(2019-01-08)
발명자
/ 주소
Cook, Robert O.
Shrewsbury, Stephen B.
Ramadan, Nabih N.
Armer, Thomas A.
출원인 / 주소
MAP PHARMACEUTICALS, INC.
대리인 / 주소
Siddiqi, Lorenz
인용정보
피인용 횟수 :
0인용 특허 :
244
초록▼
Pharmaceutical compositions containing dihydroergotamine (DHE) and methods in which DHE is administered to patients for treatment of migraine without side effects or adverse effects are disclosed. Methods for rapid treatment of migraine with DHE are disclosed comprising: dampening the peak plasma co
Pharmaceutical compositions containing dihydroergotamine (DHE) and methods in which DHE is administered to patients for treatment of migraine without side effects or adverse effects are disclosed. Methods for rapid treatment of migraine with DHE are disclosed comprising: dampening the peak plasma concentration (Cmax) and slightly delaying the peak such as to avoid activating the dopaminergic and adrenergic receptors, while achieving sufficient active binding to the serotonin receptors to provide relief from migraine symptoms within a timeframe that permits rapid resolution of migraine symptoms. Inhaler devices suitable for the methods are disclosed. Kits for practicing the methods of invention are disclosed.
대표청구항▼
1. A method of providing migraine therapy to a human subject while minimizing one or more drug-induced side effects, said method comprising: administering via pulmonary administration by oral inhalation a total dose of less than 3.0 mg of dihydroergotamine, or a salt thereof, to the human subject, w
1. A method of providing migraine therapy to a human subject while minimizing one or more drug-induced side effects, said method comprising: administering via pulmonary administration by oral inhalation a total dose of less than 3.0 mg of dihydroergotamine, or a salt thereof, to the human subject, wherein the dihydroergotamine, or the salt thereof, is administered at a rate that provides a mean peak plasma concentration (Cmax) of dihydroergotamine of less than 20,000 pg/ml within a mean time to Cmax (Tmax) that is less than 20 minutes after the administration;wherein the migraine therapy is prophylactic. 2. The method of claim 1, wherein the human subject has at least 2 to 4 headaches per month. 3. The method of claim 2, wherein the at least 2 to 4 headaches per month are severe enough to interfere with daily activity. 4. The method of claim 1, wherein the total dose of the dihydroergotamine, or the salt thereof, ranges from 1.0 mg to 2.0 mg. 5. The method of claim 1, wherein the one or more side effects is selected from the group consisting of nausea, emesis, vasospasm, paresthesia, hypertension, dizziness, anxiety, dyspnea, headache, flushing, diarrhea, rash, increased sweating, cardiac valvulopathy, pleural and retroperitoneal fibrosis, adverse cardiovascular effect, blood pressure instability and arterial constriction. 6. The method of claim 5, wherein the one or more side effects is selected from the group consisting of nausea, emesis, paresthesia and dizziness. 7. The method of claim 6, wherein the one or more side effects is nausea, emesis or both. 8. The method of claim 6, wherein the side effect is nausea. 9. The method of claim 6, wherein the side effect is emesis. 10. The method of claim 6, wherein the side effect is paresthesia. 11. The method of claim 6, wherein the side effect is dizziness. 12. The method of claim 1, wherein the Cmax of the dihydroergotamine is less than 15,000 pg/ml. 13. The method of claim 1, wherein the Cmax of the dihydroergotamine is less than 10,000 pg/ml. 14. The method of claim 1, wherein the Cmax of the dihydroergotamine is less than 7,500 pg/ml. 15. The method of claim 1, wherein the dihydroergotamine, or the salt thereof, is administered by a pressurized metered dose inhaler (pMDI). 16. The method of claim 15, wherein the pMDI is a breath-activated pMDI. 17. The method of claim 1, wherein the dihydroergotamine, or the salt thereof, is administered without administering an anti-emetic to the human subject.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (244)
Baldinger Verena (Heidelberg DEX) Unger Liliane (Ludwigshafen DEX) Szabo Laszlo (Heidelberg DEX), (S)-emopamil for the treatment of migraine.
Oxford Alexander W. (Royston GB2) Evans Brian (Buntingford GB2) Dowle Michael D. (Ware GB2) Coates Ian H. (Hertford GB2), 5-substituted-3-aminoalkyl indole derivatives for migraine.
Edwards David A. ; Caponetti Giovanni,ITX ; Hrkach Jeffrey S. ; Lotan Noah,ILX ; Hanes Justin ; Ben-Jebria Abdell Aziz ; Langer Robert S., Aerodynamically light particles for pulmonary drug delivery.
Edwards David A. ; Caponetti Giovanni,ITX ; Hrkach Jeffrey S. ; Lotan Noah,ILX ; Hanes Justin ; Ben-Jebria Abdell Aziz ; Langer Robert S., Aerodynamically light particles for pulmonary drug delivery.
Taylor Anthony James,GBX ; Neale Philip John,GBX, Aerosol formulation containing beclomethasone dipropionate and 1,1,1,2,3,3,3-heptafluoro-n-propane as propellant.
Akehurst Rachel Ann,GBX ; Taylor Anthony James,GBX ; Wyatt David Andrew,GBX, Aerosol formulation containing particulate formoterol, propellant and polar cosolvent.
Akehurst Rachel Ann,GBX ; Taylor Anthony James,GBX ; Wyatt David Andrew,GBX, Aerosol formulations containing P134A and/or P227 and particulate medicament.
Akehurst Rachel Ann (Ware GB3) Taylor Anthony James (Ware GB3) Wyatt David Andrew (Ware GB3), Aerosol formulations containing P134a and particulate medicaments.
Akehurst Rachel Ann (Ware GB3) Taylor Anthony James (Ware GB3) Wyatt David Andrew (Ware GB3), Aerosol formulations containing propellant 134a and fluticasone propionate.
Evans Richard M. (Westwood MA) Farr Stephen J. (Llandaf GB7), Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol.
Greenleaf David J. (Loughborough GB2) Howarth Peter H. (Beeston GB2) Jinks Philip A. (Mountsorrel GB2), Aerosol valve with a surfactant impregnated valve seal.
Akehurst Rachel Ann,GBX ; Taylor Anthony James,GBX ; Wyatt David Andrew,GBX, Aerosols containing salmeterol xinafoate and an anticholinergic medicament.
Phillipps Gordon H. (Wembley GB2) Bain Brian M. (Chalfont St. Peter GB2) Steeples Ian P. (Ruislip Manor GB2) Williamson Christopher (Cobham GB2), Androstane carbothioates.
Smith David W. (Clinton CT) Yevich Joseph P. (Southington CT) Williams Andrew (Middletown CT) Ruediger Edward H. (Quebec CT CAX) Combrink Keith D. (Wallingford CT) Pearce Bradley C. (East Hampton CT), Antimigraine 4-pyrimidinyl and pyridinyl derivatives of indol-3yl-alkylpiperazines.
Cipollina Joseph A. (Middletown CT) Gylys Jonas A. (Southington CT) Mattson Ronald J. (Meriden CT) Sloan Charles P. (Wallingford CT), Antimigraine derivatives of indolylcycloalkanylamines.
Bartlett Philip L. (Wilmington DE) Bivens Donald B. (Kennett Square PA) Lunger Brooks S. (Coatesville PA) Yokozeki Akimichi (Greenville DE), Azeotropic and azeotrope-like compositions of 1,1,2,2-tetrafluoroethane.
Akehurst Rachel Ann (Ware GB3) Taylor Anthony James (Ware GB3) Wyatt David Andrew (Ware GB3), Canister containing aerosol formulations containing P134a and particulate medicaments.
Akehurst Rachel Ann (Ware GB3) Taylor Anthony James (Ware GB3) Wyatt David Andrew (Ware GB3), Canister containing aerosol formulations containing P134a and particulate medicaments.
Akehurst Rachel Ann (Ware GB3) Taylor Anthony James (Ware GB3) Wyatt David Andrew (Ware GB3), Canisters containing aerosol formulations containing P134a and fluticasone propionate.
Wang Yu-chang J. (Los Altos CA) Lee William A. (Los Altos CA) Narog Blair (Palo Alto CA), Composition and method for administration of pharmaceutically active substances.
Crowley ; Jr. William F. (Newtonville MA), Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for u.
Murthy Andiappan K. S. (Convent Station NJ) Bekker Alex Y. (Teaneck NJ) Patel Kundanbhai M. (Landing NJ), Deposition of thin films using supercritical fluids.
Andersson Jan A. R. (S. Sandby SEX) Nilsson Nils G. (Lund SEX) Fagerstrm Per-Olof S. (Bjrred SEX) Wendel Thomas M. (Genarp SEX), Device in connection with an inhaler.
Jinks Philip A. (Mountsorrel GB3) Bell Alexander (Chilwell GB3) Fischer Franz X. (Riehen CHX), Drug-containing chlorofluorocarbon aerosol propellent formulations.
Hodson Peter D. (St. Paul MN) Smith David K. (St. Paul MN) Velasquez David J. (St. Paul MN) Wass Anthony C. L. (St. Paul MN), Dry powder inhalation device having a powder-loaded elongate carrier.
Hodson Peter D. ; Smith David K. ; Velasquez David J. ; Wass Anthony C.L. ; Calhoun Clyde D., Dry powder inhalation device with elongate carrier for power.
Dalby Richard N. (Richmond) Byron Peter R. (Richmond VA), Formulations for delivery of beclomethasone diproprionate by metered dose inhalers containing no chlorofluorocarbon prop.
Byron Peter R. (Richmond VA) Dalby Richard N. (Richmond VA), Formulations for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content.
Badger Alison M. (Bryn Mawr PA) Cheeseman Elaine N. (Phoenixville PA) DiMartino Michael J. (Philadelphia PA) Dorman James W. (West Chester PA) Mirabelli Christopher K. (Exton PA) Picker Donald H. (Me, Immunomodulatory azaspiranes.
Baker Raymond (Much Hadham GB2) Reeve Austin J. (Great Dunmow GB2) Street Leslie J. (Harlow GB2), Indole-substituted five-membered heteroaromatic compounds as 5-HT1agonists.
King Francis D. (Harlow) Joiner Karen A. (Harlow GB2), Indolyl carboxamides useful treating migraine, cluster headache, trigeminal neuralgia or emesis.
Robertson Alan D. (Beckenham GB2) Hill Alan P. (Beckenham GB2) Glen Robert C. (Beckenham GB2) Martin Graeme R. (Beckenham GB2), Indolyl compounds for treating migraine.
Robertson Alan D. (Beckenham GB2) Hill Alan P. (Beckenham GB2) Glen Robert C. (Beckenham GB2) Martin Graeme R. (Beckenham GB2), Indolyl tetrahydropyridines for treating migraine.
Byron Peter R. (Richmond VA) Blondino Frank E. (Richmond VA), Metered dose inhaler fomulations which include the ozone-friendly propellant HFC 134a and a pharmaceutically acceptable.
Hastings Donald R. (Elyria OH) Hendricks John A. (Vickery OH), Method and apparatus for spraying a liquid coating containing supercritical fluid or liquified gas.
Fischer Wilfried (Burscheid DEX) Mller Bernd W. (Flintbek DEX), Method and apparatus for the manufacture of a product having a substance embedded in a carrier.
Garrill Karl Andrew,GBX ; Haan Richard J. ; Herman Craig Steven ; Walker Richard Ian,GBX, Method and package for storing a pressurized container containing a drug.
Garrill Karl Andrew,GBX ; Haan Richard J. ; Herman Craig Steven ; Walker Richard Ian,GBX, Method and package for storing a pressurized container containing a drug.
Karl Andrew Garrill GB; Richard J. Haan ; Craig Steven Herman ; Richard Ian Walker GB, Method and package for storing a pressurized container containing a drug.
Greenleaf David J. (Loughborough GB3) Purewal Tarlochan S. (Leamington Spa GB3) Jinks Philip A. (Mount Sorrel GB3), Method for preparing medicinal aerosol formulation containing coated medicament.
Rouanet Stephane Fabrice ; McGovern William Edward ; Cao Wanging ; Moses John M. ; Carrillo Angel L. ; Klotz Irving M., Method of forming particles using a supercritical fluid, aerogel particles formed thereby, and antiperspirants contain.
Evans Richard M. (Norwood MA) Farr Stephen J. (Cardiff GB7), Method of preparing medical aerosol formulations including drug dissolved in reverse micelles.
Gorissen Elke (Offenburg DEX) Biskup Heike (Langenfeld DEX) Schneider Hannelore (Dusseldorf DEX), Method of producing microscopic particles made of hydrolytically decomposable polymers and containing active substances.
Cook, Robert O.; Shrewsbury, Stephen B.; Ramadan, Nabih N.; Armer, Thomas A., Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile.
Cook, Robert O.; Shrewsbury, Stephen B.; Ramadan, Nabih N.; Armer, Thomas A., Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile.
Cook, Robert O.; Shrewsbury, Stephen B.; Ramadan, Nabih N.; Armer, Thomas A., Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile.
Cook, Robert O.; Shrewsbury, Stephen B.; Ramadan, Nabih N.; Armer, Thomas A., Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile.
Armer Thomas Alex ; Evans Bryce Burwick ; Mohsen Nahed Mohsen ; Pavkov Richard Matthew ; Sudhalkar Atul M., Methods and apparatus for delivering aerosolized medication.
Armer Thomas Alex ; Evans Bryce Burwick ; Mohsen Nahed Mohsen ; Pavkov Richard Matthew ; Sudhalkar Atul M., Methods and apparatus for delivering aerosolized medication.
Armer Thomas Alex ; Evans Bryce Burwick ; Mohsen Nahed Mohsen ; Pavkov Richard Matthew ; Sudhalkar Atul M., Methods and apparatus for delivering aerosolized medication.
Subramaniam Bala ; Saim Said ; Rajewski Roger A. ; Stella Valentino, Methods for particle micronization and nanonization by recrystallization from organic solutions sprayed into a compresse.
Fassberg Julianne (New York NY) Sequeira Joel A. (New York NY) Chaudry Imtiaz A. (North Caldwell NJ) Kopcha Michael (East Brunswick NJ), Non-chlorofluorocarbon aerosol formulations.
Sweval Mark A. (Lafayette IN) Register W. Douglas (West Lafayette IN) Robin Mark L. (West Lafayette IN) Iikubo Yuichi (West Lafayette IN), Ozone friendly sterilant mixture.
Akehurst Rachel Ann,GBX ; Taylor Anthony James,GBX ; Wyatt David Andrew,GBX, Pharmaceutical aerosol formulation containing a particulate medicament, a propellant and substantially free of a surfactant.
Boyes Robert N. (St. Albans AL GB2) Tice Thomas R. (Birmingham AL) Gilley Richard M. (Birmingham AL) Pledger Kenneth L. (Huntsville AL), Pharmaceutical formulations comprising microcapsules.
Tanskanen Paavo T. (Kuopio FIX), Process for the preparation of a mixture of an anti-inflammatory steroid and a fluoro-chloro-hydrocarbon to be used as a.
Sarin Virender K. (Libertyville IL) Fox Jack L. (Lake Bluff IL) Gupta Shanker L. (Vernon Hills IL) Absolom Darryl R. (Columbus OH), Pulmonary surfactant protein fragments.
LaRoche Hans L. (Zrich CHX) Weber Markus (Zrich CHX) Zehnder Beat (Dbendorf CHX), Purification of salt-charged waste water by wet oxidation under super-critical conditions.
Manning Mark C. ; Randolph Theodore W. ; Shefter Eli ; Falk ; III Richard F., Solubilization of pharmaceutical substances in an organic solvent and preparation of pharmaceutical powders using the s.
Lee Chinsoo (Charleston WV) Hoy Kenneth L. (St. Albans WV) Donohue Marc D. (Ellicot City MD), Supercritical fluids as diluents in liquid spray application of coatings.
Liversidge Gary G. (West Chester PA) Cundy Kenneth C. (Pottstown PA) Bishop John F. (Rochester NY) Czekai David A. (Honeoye Falls NY), Surface modified drug nanoparticles.
Alkire Todd G. (Crystal MN) Sanftleben Ronald A. (Maple Grove MN) Schuehle Steven S. (Maple Grove MN), Taste masking microparticles for oral dosage forms.
Bckstrm Kjell G. E. (Lund SEX) Dahlbck Carl M. O. (Lund SEX) Edman Peter (Bjrred SEX) Johansson Ann C. B. (Lund SEX), Therapeutic preparation for inhalation.
Sakon Kiyoyuki,JPX ; Sakagami Masahiro,JPX ; Makino Yuji,JPX ; Suzuki Yoshiki,JPX ; Kobayashi Hideki,JPX, Ultrafine particle power for inhalation and method for production thereof.
Schultz Robert K. (Shoreview MN) Quessy Stephen N. (St. Paul MN), Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations.
King Francis D. (Harlow GB2) Gaster Laramie M. (Harlow GB2) Kaumann Alberto J. (Trumpington GB2) Young Rodney C. (Hertford GB2), Use of tetrahydrocarbazone derivatives as 5HT1receptor agonists.
Sarbeck Lawrence E. (Scio OR) Lee David R. (Lebanon OR) Jacoby Lawrence J. (Redding CA) Haygarth John C. (Corvallis OR) Goodwin Charles T. (Tangent OR) Crocker William A. (Salem OR), Zirconium-hafnium separation process.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.